The predominant clinical disease course of multiple sclerosis (MS) which can be treated today by a variety of different disease-modifying treatments (DMT) is characterized by reversible episodes of neurological disability (relapsing remitting form of MS (RRMS)), which frequently evolves into progressive neurological decline (secondary progressive multiple sclerosis (SPMS)) which cannot be treated by DMTs as well.
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question
D’Amico, EmanueleConceptualization
;
2017-01-01
Abstract
The predominant clinical disease course of multiple sclerosis (MS) which can be treated today by a variety of different disease-modifying treatments (DMT) is characterized by reversible episodes of neurological disability (relapsing remitting form of MS (RRMS)), which frequently evolves into progressive neurological decline (secondary progressive multiple sclerosis (SPMS)) which cannot be treated by DMTs as well.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Exp. Rev. Neurother. 2017.pdf
solo gestori archivio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
659.5 kB
Formato
Adobe PDF
|
659.5 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
